title: Dexamethasone pulse therapy in pemphigus.
abstract: Pulse therapy with high-dose glucocorticoids was introduced 20 years ago as a treatment modality for autoimmune disease and transplant rejection. The most popular dermatological indication for pulse therapy is severe pemphigus. We reviewed the sequelae of 14 patients with pemphigus who were treated by pulse therapy. Seven of them reached complete remission, although three of them needed a new pulse course due to disease flare-up. Adverse events were minor and confined to 60% of all patients: temporary facial flushing during pulse administration, sleep disturbances during the first night after pulse administration, and mood changes occurred during the week of pulse therapy. The study showed the possibility of oral instead of an intravenous mute of dexamethasone pulse administration, which makes double-blind placebo-controlled trials ethically feasible. Fifty per cent of the patients reached complete remission. This retrospective study does not allow claims on the steroid-sparing effect.
authors.affiliation: Center for Bullous Skin Diseases, Department of Dermatology, Groningen University Hospital, The Netherlands. g.g.toth@derm.azg.nl
authors.forename: G G
authors.initials: GG
authors.lastname: Tóth
authors.forename: J B
authors.initials: JB
authors.lastname: van de Meer
authors.forename: M F
authors.initials: MF
authors.lastname: Jonkman
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000188:drug therapy*; D020551:Pulse Therapy, Drug; D012074:Remission Induction; D012189:Retrospective Studies
chemical_list: D000893:Anti-Inflammatory Agents; D003907:Dexamethasone